Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 2
2008 1
2009 1
2010 3
2011 3
2012 3
2013 3
2014 2
2015 5
2016 5
2017 4
2018 3
2019 2
2020 4
2021 3
2022 2
2023 9
2024 8
2025 5
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Results by year

Filters applied: . Clear all
Page 1
212Pb-Pretargeted Theranostics for Pancreatic Cancer.
Bauer D, Carter LM, Atmane MI, De Gregorio R, Michel A, Kaminsky S, Monette S, Li M, Schultz MK, Lewis JS. Bauer D, et al. Among authors: schultz mk. J Nucl Med. 2024 Jan 2;65(1):109-116. doi: 10.2967/jnumed.123.266388. J Nucl Med. 2024. PMID: 37945380 Free PMC article.
Radiopharmaceutical Chemistry and Drug Development-What's Changed?
Kunos CA, Mankoff DA, Schultz MK, Graves SA, Pryma DA. Kunos CA, et al. Among authors: schultz mk. Semin Radiat Oncol. 2021 Jan;31(1):3-11. doi: 10.1016/j.semradonc.2020.07.006. Semin Radiat Oncol. 2021. PMID: 33246634 Free PMC article. Review.
Lead-it-EAZY! GMP-compliant production of [212Pb]Pb-PSC-PEG2-TOC.
Pretze M, Michler E, Kästner D, Kunkel F, Sagastume EA, Schultz MK, Kotzerke J. Pretze M, et al. Among authors: schultz mk. EJNMMI Radiopharm Chem. 2024 Nov 27;9(1):81. doi: 10.1186/s41181-024-00305-8. EJNMMI Radiopharm Chem. 2024. PMID: 39604560 Free PMC article.
Pre-clinical evaluation of biomarkers for the early detection of nephrotoxicity following alpha-particle radioligand therapy.
Li M, Robles-Planells C, Liu D, Graves SA, Vasquez-Martinez G, Mayoral-Andrade G, Lee D, Rastogi P, Marks BM, Sagastume EA, Weiss RM, Linn-Peirano SC, Johnson FL, Schultz MK, Zepeda-Orozco D. Li M, et al. Among authors: schultz mk. Eur J Nucl Med Mol Imaging. 2024 Apr;51(5):1395-1408. doi: 10.1007/s00259-023-06559-9. Epub 2023 Dec 14. Eur J Nucl Med Mol Imaging. 2024. PMID: 38095674 Free PMC article.
90Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy.
Menda Y, Madsen MT, O'Dorisio TM, Sunderland JJ, Watkins GL, Dillon JS, Mott SL, Schultz MK, Zamba GKD, Bushnell DL, O'Dorisio MS. Menda Y, et al. Among authors: schultz mk. J Nucl Med. 2018 Nov;59(11):1692-1698. doi: 10.2967/jnumed.117.202903. Epub 2018 Mar 9. J Nucl Med. 2018. PMID: 29523629 Free PMC article. Clinical Trial.
63 results